Recombinant exosome as well as preparation method and application thereof
By transfecting exosomes with nucleic acid molecules with exosomes loaded with nucleic acid molecules to prepare recombinant exosomes, the safety and stability of the existing gene delivery system are solved, and efficient and safe therapeutic protein delivery effect is achieved.
Patent Information
- Application Number
- CN202510290502.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-12
- Publication Date
- 2025-06-13
AI Technical Summary
There are safety and stability problems in existing gene delivery systems, viral vectors may trigger immune responses and gene mutations, while the biocompatibility and targeting of chemically synthesized liposome nanoparticles still need to be improved.
Recombinant exosomes are used as nucleic acid molecule delivery vector, and recombinant exosomes are prepared by transfecting target cells with nucleic acid molecules and culturing them. This approach avoids the potential immune response and risk of insertion mutations by viral vectors, improving the safety of treatment.
Good stability and biological activity are achieved, and the therapeutic protein can be effectively delivered to target cells, improving the safety and effectiveness of the treatment.
Smart Images

Figure CN120137909A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biotechnology, and particularly to a recombinant exosome and its preparation method and application. Background Art
[0002] Exosomes are nanoscale vesicles secreted by cells, widely present in biological fluids, with a lipid bilayer membrane structure, capable of carrying various biomolecules such as proteins and RNAs, and participating in cell - cell communication. By genetically modifying mesenchymal stem cells in vitro, the types and quantities of therapeutic proteins carried by their derived exosomes can be regulated, thereby improving the therapeutic effect; also, by engineering the surface molecules of exosomes, specific targeting can be conferred on them, enabling them to be delivered more accurately to diseased tissues or cells; the lipid bilayer membrane of exosomes can protect the internal proteins and nucleic acids from being damaged by the external environment, increasing stability and half - life; and due to the small size of exosomes, they can cross blood vessels and tissue barriers and reach the diseased site, which is particularly important for treating some diseases that are difficult to access.
[0003] Traditional gene delivery systems, such as viral vectors and chemically synthesized liposome nanoparticles (LNPs), although they can effectively transfect target cells, have problems such as safety and stability. Viral vectors may trigger immune responses and gene mutations, while the biocompatibility and targeting of chemically synthesized nanoparticles still need to be improved.
[0004] Therefore, finding new safe and efficient gene delivery systems is of great significance for the treatment of related diseases. Summary of the Invention
[0005] Based on this, the present application provides a recombinant exosome and its preparation method and application. This recombinant exosome has good stability and biological activity and can effectively deliver nucleic acid molecules to target cells.
[0006] The specific technical solutions are as follows:
[0007] On the one hand, the present application provides a preparation method of a recombinant exosome, including the following steps:
[0008] Transfect target cells with exosomes loaded with nucleic acid molecules and culture them to prepare recombinant exosomes;
[0009] The nucleic acid molecule sequentially includes a promoter sequence, a sequence encoding β - globin, 5'-UTR, a target gene sequence, a sequence encoding α - globin, 3'-UTR, and a transcription terminator sequence from the 5' end to the 3' end.
[0010] This application has developed a new method for preparing recombinant exosomes. This method transfects target cells with exosomes loaded with nucleic acid molecules and then cultures them, which can not only produce recombinant exosomes of specific proteins, but also has high flexibility and controllability. Using recombinant exosomes as nucleic acid molecule delivery vectors avoids the immune responses and risks of insertional mutations that may be caused by viral vectors, and improves the safety of treatment. The recombinant exosomes produced by the preparation method of this application show good stability and biological activity in cell culture and in vivo experiments, and can effectively deliver therapeutic proteins to target cells. The recombinant exosomes of this application can be mass-produced by genetic engineering techniques, and the genes carried by them can be precisely adjusted, making it more operable and expandable in clinical applications. This technology has great potential in clinical applications, especially in the fields that require precise control of gene expression and protein delivery.
[0011] In some of these embodiments, the nucleic acid molecule includes at least one of plasmid DNA, mRNA, siRNA, miRNA, and circular RNA.
[0012] In one embodiment, the target gene sequence can encode a target protein, and the target protein is used to promote cell proliferation, differentiation, migration and survival, and induce the generation of induced pluripotent stem cells.
[0013] Optionally, the target protein includes at least one of epidermal growth factor, basic fibroblast growth factor, and Yamanaka factors.
[0014] In one embodiment, the gene encoding the epidermal growth factor includes the EGF gene, and the sequence is as shown in SEQ ID NO: 1;
[0015] and / or, the gene encoding the basic fibroblast growth factor includes the bFGF gene, and the sequence is as shown in SEQ ID NO: 2;
[0016] and / or, the gene encoding the Yamanaka factors includes at least one of the Sox2 gene, Oct4 gene, Klf-4 gene, and c-Myc gene.
[0017] In one embodiment, the sequence of the Sox2 gene is as shown in SEQ ID NO: 3;
[0018] and / or, the sequence of the Oct4 gene is as shown in SEQ ID NO: 4;
[0019] and / or, the sequence of the Klf-4 gene is as shown in SEQ ID NO: 5;
[0020] and / or, the sequence of the c-Myc gene is as shown in SEQ ID NO: 6.
[0021] In one embodiment, the sequence of the nucleic acid molecule is any one of those shown in SEQ ID NO: 7-12.
[0022] In one embodiment, the loading methods of the nucleic acid molecule in the exosomes loaded with the nucleic acid molecule include a microfluidic system, electroporation, ultrasound, liposome fusion, or direct incubation.
[0023] Another aspect of the present application provides a recombinant exosome, comprising a nucleic acid molecule encapsulated by the exosome, and the nucleic acid molecule sequentially includes a promoter sequence, a sequence encoding β-globin, a 5'-UTR, a target gene sequence, a sequence encoding α-globin, a 3'-UTR, and a transcription terminator sequence from the 5' end to the 3' end.
[0024] Another aspect of the present application also provides a pharmaceutical composition, which comprises the recombinant exosome prepared by the above-mentioned recombinant exosome method or the above-mentioned recombinant exosome, and a pharmaceutically acceptable auxiliary component.
[0025] Another aspect of the present application also provides the use of the recombinant exosome prepared by the preparation method of the above-mentioned recombinant exosome, the above-mentioned recombinant exosome, or the above-mentioned pharmaceutical composition in the preparation of a drug for treating wound repair and healing, tissue repair, wound healing, or preventing scar hyperplasia. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 It is a schematic structural diagram of the nucleic acid molecule in Example 1 of the present application; wherein CMV promoter represents the CMV promoter, T7 Promoter represents the T7 promoter, Signal represents the signal molecule, bFGF / EGF / Yamanaka factors represent epidermal growth factor, basic fibroblast growth factor, or Yamanaka factors, and T7 terminator represents the T7 terminator;
[0027] Figure 2Schematic diagram of subsequent transfection in Example 1 of this application; T7 Polymerase represents T7 RNA polymerase, DNA Template represents DNA template, PolyA Polymerase represents polyadenylate polymerase, NTP represents ribonucleoside triphosphate, Magnesium ion represents magnesium ion, In vitro transcription represents in vitro transcription, Purification represents purification, mRNA represents messenger RNA, Exosome represents exosome, Encapsulation represents encapsulation, Target gene represents target gene, mRNA-Exosome Syn-Exo represents mRNA-exosome complex, DNA-Exosome Syn-Exo represents DNA-exosome complex, Protein of interest represents target protein;
[0028] Figure 3 Schematic diagram of the preparation of recombinant exosomes in Example 1 of this application; Syn-Exo represents complex, Cytoplasm represents cytoplasm, Nucleus represents nucleus, Protein of interest represents target protein, Recombinant Exosome represents recombinant exosome;
[0029] Figure 4 Results diagram of transfection of nucleic acid molecule-exosome complexes into various cell lines in Example 1 of this application; mRNA normalized with ACTB represents that mRNA is normalized with ACTB as a reference, ACTB refers to the β-actin gene, Expression of hEGF in Recombinant Exosome represents the expression of human epidermal growth factor (hEGF) in recombinant exosomes, Expression of hbFGF in Recombinant Exosome represents the expression of human basic fibroblast growth factor (hbFGF) in recombinant exosomes, Intracellular hEGF Expression represents the expression of intracellular human epidermal growth factor (hEGF), hbFGF-Syn-Exo represents hbFGF-synthetic exosome;
[0030] Figure 5 Results diagram of the promotion of the proliferation of 293T cells and fibroblasts by recombinant exosomes in Example 1 of this application; Wound Closure represents wound closure;
[0031] Figure 6 Results diagram of cytotoxicity in Example 1 of this application;
[0032] Figure 7 This is the result graph of the generation of iPSCs induced by recombinant exosomes in Example 1 of this application; BJ cells / 293 cells represent BJ cells or 293 cells, Recombinant Exosome (Yamanaka) represents recombinant exosomes (Yamanaka factors), Replace culture medium represents changing the culture medium, Suspended culture represents suspension culture, Attached culture (Geltrex treated) represents adherent culture (the surface of the culture vessel is treated with Geltrex), Geltrex is an extracellular matrix (ECM) analogue, the main components of which are laminin, collagen, and nidogen, etc., which can simulate the extracellular matrix environment in vivo and promote the adherent growth of cells, Attached culture represents adherent culture, Evaluate iPSCs characteristics represents evaluating the characteristics of induced pluripotent stem cells (iPSCs);
[0033] Figure 8 This is the result graph of AP staining in Example 1 of this application. Detailed implementation manners
[0034] To make the above objects, features, and advantages of this application more obvious and understandable, the detailed implementation manners of this application are described in detail. Many specific details are set forth in the following description to facilitate a thorough understanding of this application. However, this application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without departing from the connotation of this application. Therefore, this application is not limited by the specific embodiments disclosed below.
[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the technical field to which this application belongs. The terms used in the specification of this application herein are only for the purpose of describing specific embodiments and are not intended to limit this application. Unless otherwise specifically stated, various raw materials, reagents, instruments, and equipment used in this application can be obtained through the market or can be prepared by existing methods.
[0036] As used herein, the selection scope of the terms "and / or", "or / and", and "and / or" includes any one of two or more related listed items, and also includes any and all combinations of the related listed items. The said any and all combinations include combinations of any two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, this technical solution undoubtedly includes the technical solution connected by "logical AND", and also undoubtedly includes the technical solution connected by "logical OR". For example, "A and / or B" includes three parallel solutions: A, B, and A + B. Another example is the technical solution of "A, and / or, B, and / or, C, and / or, D", which includes any one of A, B, C, and D (that is, the technical solution connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, it includes combinations of any two or any three of A, B, C, and D, and also includes the four-item combination of A, B, C, and D (that is, the technical solution connected by "logical AND").
[0037] In this application, the terms "multiple", "multiple types", "multiple times", "multiple elements", etc., unless otherwise specified, refer to a quantity greater than 2 or equal to 2. For example, "one or more" means one or greater than or equal to two.
[0038] As used herein, "its combination", "any combination thereof", "any combination mode thereof", etc. include all suitable combination modes of any two or more than two items in the listed items.
[0039] In this article, the "suitable" in "suitable combination mode", "suitable mode", "any suitable mode", etc. is subject to being able to implement the technical solution of this application, solve the technical problems of this application, and achieve the expected technical effects of this application.
[0040] In this article, "preferred", "better", "more preferable", "it is advisable" are only used to describe the implementation modes or embodiments with better effects, and it should be understood that they do not constitute a limitation on the protection scope of this application.
[0041] In this application, "further", "even further", "especially", etc. are used for descriptive purposes, indicating differences in content, but should not be understood as a limitation on the protection scope of this application.
[0042] In this application, "optionally", "optional", "optional" mean that it can be either present or absent, that is, it refers to any one of the two parallel solutions of "present" or "absent". If "optional" appears multiple times in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction relationship, each "optional" is independent of each other.
[0043] In the present application, "nucleic acid" or "nucleic acid molecule" refers to any DNA or RNA molecule and is used interchangeably with polynucleotide. When referring to a nucleic acid or nucleic acid sequence encoding a specific protein and / or peptide, the nucleic acid or nucleic acid sequence preferably further comprises regulatory sequences respectively, so as to allow expression in a suitable host such as a human, that is, transcription and / or translation of the nucleic acid sequence encoding a specific protein or peptide.
[0044] In the present application, "5'-UTR" refers to a part of a nucleic acid molecule that is located at the 5' (i.e., "upstream") of the open reading frame and is not translated into a protein. In the context of the present disclosure, the 5'-UTR starts at the transcription start site and terminates at a nucleotide before the start codon of the open reading frame.
[0045] In the present application, "3'-UTR" refers to a part of a nucleic acid molecule that is located at the 3' (i.e., "downstream") of the open reading frame and is not translated into a protein. In the context of the present disclosure, the 3'-UTR corresponds to the sequence between the stop codon (preferably immediately adjacent to the stop codon of the protein-coding sequence) of the protein-coding sequence and the polyadenylation sequence at the 3'.
[0046] In the present application, the target protein generally includes any protein that can be encoded by a nucleic acid sequence having at least one coding region and can be expressed under appropriate conditions to produce a functional protein product.
[0047] In the present application, a growth factor refers to a class of polypeptide substances that regulate multiple effects such as cell growth and other cell functions by binding to specific and high-affinity cell membrane receptors.
[0048] In the present application, among the technical features described in an open-ended manner, it includes a closed technical solution composed of the listed features, and also includes an open technical solution containing the listed features.
[0049] As shown in the background art, exosomes, as natural biological nanoparticles, are regarded as a potential gene and drug delivery carrier due to their good biocompatibility and low immunogenicity. However, the proteins and RNAs carried in natural exosomes are spontaneously released by the mother cells, making it difficult to control their contents and there may be certain biosafety risks. In particular, the molecules released during the treatment process may trigger uncertain biological reactions. Although natural MSC exosomes have certain therapeutic potential, they cannot flexibly carry or express designated genes or proteins, which limits their application scope. Although natural MSC exosomes show good therapeutic effects in some disease models, the types and amounts of biomolecules they carry are limited and they cannot enhance the expression of specific proteins. Although natural MSC exosomes have certain potential in the intercellular transfer of RNA molecules, they cannot precisely carry or introduce exogenous genes, which limits their application in gene therapy. Moreover, the production of natural exosomes depends on the secretion process of cells, making it difficult to precisely control the contents contained in exosomes. In addition, the production yield and purity of natural exosomes may be affected by the cell state, thus limiting their operability in large-scale clinical applications.
[0050] Traditional gene delivery systems mainly include the following seven types. One is viral vector gene therapy: Viral vectors such as adeno-associated virus (AAV), lentivirus (LV), etc. are widely used in gene therapy and can effectively deliver specific therapeutic genes into the cells of patients. However, viral vectors may trigger immune responses and there is a risk of insertional mutagenesis. One is liposome nanoparticle (LNP)-mediated gene delivery: LNP is a non-viral gene delivery system that has been used for the delivery of siRNA and mRNA. However, LNP may have problems of insufficient stability and targeting. Another is the bioreactor based on animal or plant cells: Recombinant proteins are produced by using animal cell lines (such as Chinese hamster ovary cells CHO) or plant cell cultures. However, traditional bioreactor technology usually does not involve exosomes. Another is stem cell-based gene therapy: Utilizing the pluripotency of stem cells, gene correction or enhancement is carried out through gene editing technologies such as CRISPR / Cas9. However, stem cell technology poses challenges in terms of ethics and operation. Another is the production of secreted proteins based on engineered cells: Host cells are transfected or transduced to secrete therapeutic proteins. However, the proteins secreted by engineered cells may lack correct post-modification, affecting their functions. Recombinant exosomes can provide a protein post-modification environment closer to that in vivo. Another is gene therapy using natural exosomes: Exosomes are isolated from natural sources (such as blood, urine), and attempts are made to load therapeutic nucleic acids or proteins through physical or chemical methods. However, it is difficult to control the yield and quality of natural exosomes. Another is the therapeutic application of microRNA or small interfering RNA (siRNA): RNA molecules are used for gene silencing to treat certain diseases. However, the delivery efficiency and stability of RNA molecules may be limited.
[0051] Based on this, an embodiment of the present application provides a method for preparing recombinant exosomes, including the following steps: Transfecting target cells with exosomes loaded with nucleic acid molecules and culturing to prepare recombinant exosomes; The above nucleic acid molecule sequentially includes a promoter sequence, a sequence encoding β-globin, 5'-UTR, a target gene sequence, a sequence encoding α-globin, 3'-UTR, and a transcription terminator sequence from the 5' end to the 3' end.
[0052] This application has developed a new method for preparing recombinant exosomes. This method transfects target cells with exosomes loaded with nucleic acid molecules and then cultures them. It can not only produce recombinant exosomes of specific proteins, but also has high flexibility and controllability. Using recombinant exosomes as a nucleic acid molecule delivery vector avoids the immune response and the risk of insertional mutagenesis that may be caused by viral vectors, and improves the safety of treatment. The recombinant exosomes produced by the preparation method of this application show good stability and biological activity in cell culture and in vivo experiments, and can effectively deliver therapeutic proteins to target cells. The recombinant exosomes of this application can be mass-produced by genetic engineering technology, and the genes carried by them can be precisely adjusted, making it more operable and expandable in clinical applications. This technology has great potential in clinical applications, especially in fields that require precise control of gene expression and protein delivery.
[0053] In some of these embodiments, the above-mentioned nucleic acid molecules include at least one of plasmid DNA, mRNA, siRNA, miRNA, and circular RNA.
[0054] In a specific example, the above-mentioned nucleic acid molecule includes circular RNA, and the nucleic acid molecule includes a promoter sequence and, in sequence downstream of the promoter sequence, a sequence encoding β-globin, a 5'-UTR, a target gene sequence, a sequence encoding α-globin, a 3'-UTR, and a transcription terminator sequence.
[0055] In some of these embodiments, the above-mentioned target gene sequence can encode a target protein, and the target protein is used to promote cell proliferation, differentiation, migration, and survival, as well as to induce the generation of induced pluripotent stem cells.
[0056] In some of these embodiments, the above-mentioned target proteins include at least one of epidermal growth factor, basic fibroblast growth factor, and Yamanaka factors.
[0057] In some of these embodiments, the gene encoding the above-mentioned epidermal growth factor includes the EGF gene, and the sequence is as shown in SEQ ID NO:1; specifically: ATGCTGCTCACTCTTATCATTCTGTTGCCAGTAGTTTCAAAAAATAGTGACTCTGAATGTCCCCTGTCCCACGATGGGTACTGCCTCCATGATGGTGTGTGCATGTATATTGAAGCATTGGACAAGTATGCATGCAACTGTGTTGTTGGCTACATCGGGGAGCGATGTCAGTACCGAGACCTGAAGTGGTGGGAACTGCGCTGA.
[0058] In some of these embodiments, the gene encoding the above-mentioned basic fibroblast growth factor includes the bFGF gene, and the sequence is as shown in SEQ ID NO:2; specifically: ATGGCAGCCGGGAGCATCACCACGCTGCCCGCCTTGCCCGAGGATGGCGGCAGCGGCGCCTTCCCGCCCGGCCACTTCAAGGACCCCAAGCGGCTGTACTGCAAAAACGGGGGCTTCTTCCTGCGCATCCACCCCGACGGCCGAGTTGACGGGGTCCGGGAGAAGAGCGACCCTCACATCAAGCTACAACTTCAAGCAGAAGAGAGAGGAGTTGTGTCTATCAAAGGAGTGTGTGCTAACCGTTACCTGGCTATGAAGGAAGATGGAAGATTACTGGCTTCTAAATGTGTTACGGATGAGTGTTTCTTTTTTGAACGATTGGAATCTAATAACTACAATACTTACCGGTCAAGGAAATACACCAGTTGGTATGTGGCACTGAAACGAACTGGGCAGTATAAACTTGGATCCAAAACAGGACCTGGGCAGAAAGCTATACTTTTTCTTCCAATGTCTGCTAAGAGCTGA。
[0059] In some of these embodiments, the gene encoding the above-mentioned Yamanaka factors includes at least one of the Sox2 gene, Oct4 gene, Klf-4 gene, and c-Myc gene.
[0060] In some of these embodiments, the sequence of the above-mentioned Sox2 gene is as shown in SEQ ID NO:3; specifically: ATGTATAACATGATGGAGACGGAGCTGAAGCCGCCGGGCCCGCAGCAAACTTCGGGGGGCGGCGGCGGCAACTCCACCGCGGCGGCGGCCGGCGGCAACCAGAAAAACAGCCCGGACCGCGTCAAGCGGCCCATGAATGCCTTCATGGTGTGGTCCCGCGGGCAGCGGCGCAAGATGGCCCAGGAGAACCCCAAGATGCACAACTCGGAGATCAGCAAGCGCCTGGGCGCCGAGTGGAAACTTTTGTCGGAGACGGAGAAGCGGCCGTTCATCGACGAGGCTAAGCGGCTGCGAGCGCTGCACATGAAGGAGCACCCGGATTATAAATACCGGCCCCGGCGGAAAACCAAGACGCTCATGAAGAAGGATAAGTACACGCTGCCCGGCGGGCTGCTGGCCCCCGGCGGCAATAGCATGGCGAGCGGGGTCGGGGTGGGCGCCGGCCTGGGCGCGGGCGTGAACCAGCGCATGGACAGTTACGCGCACATGAACGGCTGGAGCAACGGCAGCTACAGCATGATGCAGGACCAGCTGGGCTACCCGCAGCACCCGGGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCCCATGCACCGCTACGACGTGAGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGCCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGGCTCTTGGCTCCATGGGTTCGGTGGTCAAGTCCGAGGCCAGCTCCAGCCCCCCTGTGGTTACCTCTTCCTCCCACTCCAGGGCGCCCTGCCAGGCCGGGGACCTCCGGGACATGATCAGCATGTATCTCCCCGGCGCCGAGGTGCCGGAACCCGCCGCCCCCAGCAGACTTCACATGTCCCAGCACTACCAGAGCGGCCCGGTGCCCGGCACGGCCATTAACGGCACACTGCCCCTCTCACACATGTGA。
[0061]
[0062]
[0063]
[0064] In some of these embodiments, the sequences of the above nucleic acid molecules are any one of those shown in SEQ ID NO:7-12.
[0065] This technology can not only utilize human cells, but also use animal or plant cells to produce recombinant exosomes, ensuring that they carry human medical proteins, reducing ethical issues, avoiding virus contamination, and enhancing the safety and controllability of production. Recombinant exosomes can encapsulate specific genes and efficiently express therapeutic proteins in target cells. This flexibility meets the needs of personalized treatment and is particularly suitable for gene therapy, regenerative medicine, and drug delivery.
[0066] In some of these embodiments, the loading methods of the nucleic acid molecules in the above exosomes loaded with nucleic acid molecules include microfluidic systems, electroporation, ultrasound, liposome fusion, or direct incubation.
[0067] It is understandable that the above production using a microfluidic system and the subsequent steps such as dialysis and ultrasonic treatment are used to collect exosomes. The above production process can be adjusted according to the production scale and requirements. For example: large-scale bioreactor: It can replace the microfluidic system to achieve large-scale production.
[0068] In a specific example, during the process of loading nucleic acid molecules into the above microfluidic system, lipid components are prepared using DLin-MC3-DMA, DOPE, cholesterol, and PEG-2000-DMG in a certain ratio. The lipid components can be adjusted according to the characteristics of exosomes or specific applications. For example: One is other cationic lipids: It can be used to enhance the efficiency of gene loading. Another is polyethylene glycol modification (PEGylation): It can further extend the circulation time of exosomes or nanocarriers in the body.
[0069] It is understandable that by changing the lipid components, the efficiency of gene delivery, targeting, and the stability of nanoparticles can be further optimized.
[0070] In some of these embodiments, the above target cells include one or more of HEK 293 cells, fibroblasts, amniotic cells, epithelial cells, mesenchymal stem cells, human embryonic kidney cells, HT-1080 cells, HeLa cells, PERC-6 cells, and CEVEC cells.
[0071] It is understandable that the above target cells do not necessarily have to be human cells. Animal or plant cells can also be used to produce non-human recombinant exosomes but carrying human medical proteins. The prepared recombinant exosomes have the advantages of good biocompatibility, low immunogenicity, high safety, and can be produced on a large scale, providing a new strategy for gene therapy and protein delivery.
[0072] Another embodiment of the present application also provides a recombinant exosome, which includes a nucleic acid molecule encapsulated by the exosome. The nucleic acid molecule sequentially includes a promoter sequence, a sequence encoding β-globin, a 5'-UTR, a target gene sequence, a sequence encoding α-globin, a 3'-UTR, and a transcription terminator sequence from the 5' end to the 3' end.
[0073] Another embodiment of the present application also provides a pharmaceutical composition, which includes the recombinant exosome prepared by the above recombinant exosome method or the above recombinant exosome, and a pharmaceutically acceptable auxiliary component.
[0074] In some of these embodiments, the pharmaceutically acceptable auxiliary component includes a pharmaceutically acceptable excipient.
[0075] The pharmaceutically acceptable excipient can play different functional roles and includes one or more of binders, lubricants, glidants, diluents, and disintegrants.
[0076] In one of the embodiments, the binder includes one or several of povidone K30, copovidone, sodium carboxymethylcellulose, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.
[0077] In one of the embodiments, the lubricant includes one or several of magnesium stearate, talc powder, and polyethylene glycols.
[0078] In one of the embodiments, the glidant includes one or several of silica, colloidal silicon dioxide, calcium hydrogen phosphate, tricalcium phosphate, and milk mineral salts.
[0079] In one of the embodiments, the diluent includes one or several of microcrystalline cellulose, isomalt, starch, dextrin, lactose, pregelatinized starch, mannitol, sorbitol, and erythritol.
[0080] In one of the embodiments, the disintegrant includes one or several of crospovidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, and dry starch.
[0081] Another embodiment of the present application also provides the use of the recombinant exosome prepared by the preparation method of the above recombinant exosome, the above recombinant exosome, or the above pharmaceutical composition in the preparation of a drug for treating wound repair and healing, tissue repair, wound healing, or preventing scar hyperplasia.
[0082] The present application will be further described below in conjunction with specific embodiments, but it should not be construed as a limitation on the protection scope of the present application. For the raw materials involved in the following specific embodiments, unless otherwise specified, they can all be obtained commercially. For the instruments used, unless otherwise specified, they can all be obtained commercially. For the processes involved, unless otherwise specified, they are all conventional selections of those skilled in the art.
[0083] Example 1
[0084] I. Experimental procedures
[0085] 1. Design of DNA oligonucleotides
[0086] Embed the target gene sequences (such as: bFGF, EGF, and Yamanaka factors) between the human β-globin 5'UTR and the human α-globin 3'UTR, and add a T7 terminator at the 5' end of the structure to terminate transcription (see Figure 1 ). The sequences of the DNA oligonucleotides are shown in SEQ ID NO:7-12 respectively, specifically
[0087] SEQ ID NO:7: ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACCTGTACAGCCACCCTGGATTTTTTTCGGGTAGTGGAAAACCAGCAGCCTCCCGCGACGATGCTGCTCACTCTTATCATTCTGTTGCCAGTAGTTTCAAAAAATAGTGACTCTGAATGTCCCCTGTCCCACGATGGGTACTGCCTCCATGATGGTGTGTGCATGTATATTGAAGCATTGGACAAGTATGCATGCAACTGTGTTGTTGGCTACATCGGGGAGCGATGTCAGTACCGAGACCTGAAGTGGTGGGAACTGCGCTGAGCGGCCGCGCTGGAGCCTCGGTAGCCGTTCCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGGCCCTTCCTGGTCTTTGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT.
[0088] SEQ ID NO:8: ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACCTGTACAGCCACCCTGGATTTTTTTCGGGTAGTGGAAAACCAGCAGCCTCCCGCGACGATGGCAGCCGGGAGCATCACCACGCTGCCCGCCTTGCCCGAGGATGGCGGCAGCGGCGCCTTCCCGCCCGGCCACTTCAAGGACCCCAAGCGGCTGTACTGCAAAAACGGGGGCTTCTTCCTGCGCATCCACCCCGACGGCCGAGTTGACGGGGTCCGGGAGAAGAGCGACCCTCACATCAAGCTACAACTTCAAGCAGAAGAGAGAGGAGTTGTGTCTATCAAAGGAGTGTGTGCTAACCGTTACCTGGCTATGAAGGAAGATGGAAGATTACTGGCTTCTAAATGTGTTACGGATGAGTGTTTCTTTTTTGAACGATTGGAATCTAATAACTACAATACTTACCGGTCAAGGAAATACACCAGTTGGTATGTGGCACTGAAACGAACTGGGCAGTATAAACTTGGATCCAAAACAGGACCTGGGCAGAAAGCTATACTTTTTCTTCCAATGTCTGCTAAGAGCTGAGCGGCCGCGCTGGAGCCTCGGTAGCCGTTCCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCACCGGCCCTTCCTGGTCTTTGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT。
[0089] SEQ ID NO:9(Sox 2):
[0090]
[0091] SEQ ID NO:11 (Klf-4):
[0092]
[0093]
[0094] 2. Preparation of Plasmid DNA
[0095] DNA Vector Construction: The DNA vector includes a CMV promoter, human β-globin, a 5'-UTR, a coding region, human α-globin, a 3'-UTR, and a transcription terminator. The coding region can encode target proteins such as epidermal growth factor, basic fibroblast growth factor, and Yamanaka factors.
[0096] The specific preparation method is as follows: Use pcDNA3.1(+) as the backbone of the DNA vector, perform partial digestion at the SacI and XbaI endonuclease sites (the SacI site at the end of the CMV promoter), and ligate with the following target genes (5'-3'): SacI endonuclease site, T7 promoter, human β-globin, a 5'-UTR, a coding region, human α-globin, a 3'-UTR, and a T7 transcription terminator. The coding region can encode target proteins such as epidermal growth factor, basic fibroblast growth factor, and Yamanaka factors. Transform the ligated plasmid DNA into TOP10 competent cells to multiply the plasmid DNA, and then purify and extract the plasmid DNA from the transformed TOP10 cells.
[0097] 3. Preparation of mRNA
[0098] mRNA is generated through an in vitro transcription and purification process.
[0099] The specific steps are as follows: For the plasmid DNA as described above, use DNA primers to amplify and purify the target fragments of the CMV promoter, human β-globin, a 5'-UTR, a coding region, human α-globin, a 3'-UTR, and a transcription terminator. The coding region can encode target proteins such as epidermal growth factor, basic fibroblast growth factor, and Yamanaka factors, and then mix with the following in vitro transcription mRNA mixture: T7 polymerase, PolyA polymerase, nucleoside triphosphates, and a buffer solution containing salts and cofactors. Incubate the reaction mixture at room temperature for 2 hours. After the transcription reaction is completed, purify the mRNA through a column to remove enzymes, nucleotides, and other reaction components.
[0100] 4. Preparation of Exosomes
[0101] The specific steps are as follows: Use the medium of hMSCs at 37°C, 5% CO 2Cells were cultured under the following conditions until a cell density of 70 - 80% was reached. The culture medium was replaced with low - serum medium. After 48 hours, the culture supernatant was collected, centrifuged at 500 x g for 10 minutes, and the supernatant was transferred to a new centrifuge tube. Then it was centrifuged at 100,000 x g for 2 hours. The exosome pellet was resuspended in PBS and then ultra - centrifuged again to precipitate the exosomes.
[0102] 5. Preparation of DNA / mRNA - exosome complexes
[0103] The specific steps are as follows: A microfluidic system was developed to encapsulate plasmid DNA / PCR DNA into human or non - human exosomes. Fabrication of DNA - exosome complexes by microfluidics: DNA - exosome complexes encapsulating target plasmid DNA encoding (e.g., epidermal growth factor, basic fibroblast growth factor, and Yamanaka factors) were generated by a microfluidic system. The microfluidic system consists of an injection pump, two 20 - cm - long silica microtubes, a customized microfluidic chip, and two 10 - mL syringes. Before the experiment, the whole system was connected and sterilized with 5 mL of 75% ethanol, and then thoroughly rinsed with 5 mL of PBS. The lipid component was prepared by dissolving DLin - MC3 - DMA (AVT (Shanghai) Pharmaceutical Tech Co., Ltd), DOPE (AVT (Shanghai) Pharmaceutical Tech Co, Ltd), cholesterol (AVT (Shanghai) Pharmaceutical Tech Co, Ltd), and PEG - 2000 - DMG (MedChemExpress LL) in EtOH at a molecular ratio of 50:10:39:1. The aqueous component was prepared by diluting plasmid DNA and human or non - human exosomes in 25 mM sodium acetate to 0.116 mg / mL (pH 4). The lipid solution and the aqueous solution were mixed through the microfluidic system at flow rates of 5 mL / min and 15 mL / min, respectively. The generated DNA - exosome complex solution was sonicated and filtered through a 100 - nm filter, and then dialyzed in PBS for 24 hours. Then, through Pierce TM Protein concentrator PES, 10K MWCO, concentrated the solution to a final concentration of 0.348 mg / mL.
[0104] 5. Transfection of 293T cells with DNA / mRNA - exosome complexes
[0105] The specific steps are as follows: After 1 mL of complete medium is thoroughly mixed with the mRNA-exosome complex, it is added to the cells. After 6 hours of incubation, the transfection medium containing the mRNA-exosome complex is replaced with fresh growth medium. At 72 hours after transfection, the cells are collected for further experiments, and the transfection efficiency is analyzed by Western blotting. Specifically, as Figure 2 and Figure 3 shown.
[0106] 6. Isolation of recombinant exosomes
[0107] The specific steps are as follows: Cells are cultured in DMEM medium at 37 °C and 5% CO 2 until a cell density of 70 - 80% is reached. The medium is replaced with low-serum medium. After 48 hours, the culture supernatant is collected, centrifuged at 500 x g for 10 minutes, and the upper liquid is transferred to a new centrifuge tube. It is then centrifuged at 100,000 x g for 2 hours. The exosome pellet is resuspended in PBS, and then ultracentrifuged again to pellet the exosomes.
[0108] 7. Detection
[0109] 7.1 qPCR test
[0110] The specific steps are as follows: 293T cells and cells transfected with the EGF / bFGF mRNA complex are collected, and the cells are lysed with RNAzol (Molecular Research Center Inc.). RNA is extracted according to the manufacturer's manual, and the concentration is measured using a Qubit 4 fluorometer and a Qubit TM RNA Assay Kit (Invitrogen). The RNA is initially reverse-transcribed into complementary DNA (cDNA) using a Luna One Step RT-qPCR Kit (NEW ENGLAND Biolabs INC) and a QuantStudio TM 3 Real-Time PCR System (Applied Biosystems TM ). Subsequently, the cDNA is amplified using DNA-dependent DNA polymerase and quantified by quantitative polymerase chain reaction (qPCR). The primer sequences are from the National Center for Biotechnology Information (NCBI) database, and gene expression is normalized relative to β-actin.
[0111] 7.2 Western blot to detect the corresponding protein levels of EGF and bFGF in the culture medium and recombinant exosomes
[0112] The specific steps are as follows: Cells were collected after different treatments. These cells were lysed using RIPA buffer (Thermo Fisher Scientific) supplemented with a protease inhibitor cocktail (Bio station). To determine the protein concentration, the DC (detergent-compatible) protein assay (Bio-Rad) was employed. A total of 20 μg of protein was loaded onto a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane using a Life Technologies power supply (Invitrogen). Subsequently, the membrane was blocked with TBST / 5% non-fat milk powder (Quaker) and incubated overnight at 4 °C with primary antibodies (β-actin (Gene Tex), bFGF (Invitrogen), EGF (Invitrogen), Sox2, Oct4, Klf4, and c-Myc (ProteinTech)). Then, the membrane was incubated with a secondary antibody (goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, HRP) (Invitrogen) for 2 hours at room temperature. Before images were captured using the Invitrogen TM iBright imaging system, the membrane was pre-treated with ECL solution under lightless conditions.
[0113] II. Result analysis:
[0114] 1. Transfection of nucleic acid molecule-exosome complexes into 293T cells, human fibroblasts, and MSC cells
[0115] The qPCR test results indicated that within the first 8 hours of culture, the expression levels of recombinant exosomes containing EGF and bFGF remained stable and only slightly decreased at the 24-hour time point, confirming the stability of the designed mRNA (see Figure 4 a) in). To further verify the research results, Western blot analysis was performed to evaluate the corresponding protein levels of EGF and bFGF in the culture medium and recombinant exosomes. 293T cells and recombinant exosomes were collected at 0, 2, 4, 6, 8, and 24 hours after transfection with the EGF-DNA exosome complex and the bFGF-DNA exosome complex. The results showed that the protein expression of EGF and bFGF in the cells increased significantly at 4 hours after transfection (see Figure 4 d, e) in). On the other hand, the levels of EGF and bFGF in the recombinant exosomes increased significantly at 6 hours after transfection (see Figure 4 b, c) in). In addition, 293T cells and human fibroblast BJ cells were transfected with bFGF plasmid DNA, and the bFGF protein expression in the recombinant exosomes increased significantly (see Figure 4in f, g). In this study, MSC cells were transfected with bFGF plasmid DNA and bFGF-mRNA. At 72 hours after transfection, the expression of bFGF increased significantly in both the plasmid DNA and mRNA treatment groups (see Figure 4 in h). The above results indicate that the plasmid DNA and mRNA-exosome platforms are efficient in transfecting various cell lines as well as MSC cells to produce recombinant exosomes containing the target protein.
[0116] 2. Verification of the biological functions of recombinant exosomes
[0117] This application explored the biological functions of recombinant exosomes containing EGF and bFGF in several cell types. The proliferation of 293T and fibroblasts supplemented with bFGF and EGF recombinant exosomes (specifically refer to experimental step 5) increased significantly at 24 hours and 48 hours (see Figure 5 in a, b). Fibroblasts are actively involved in tissue repair, wound healing, and maintaining the structural integrity of connective tissues. Migration and proliferation are two basic functions of fibroblasts in these processes. The addition of bFGF and EGF recombinant exosomes significantly stimulated the proliferation ability of human fibroblast BJ cells, especially at the 48-hour time point. In the group transfected with bFGF and EGF plasmid DNA, the proliferation rate was approximately 1.3 times faster than that of the control group (see Figure 5 in c, d). When tissues are damaged, fibroblasts are recruited to the injured site. Migration is the process by which fibroblasts move to the injured area in response to various signaling molecules released during the inflammatory response, such as growth factors and cytokines. Our results show that high bFGF expression can accelerate fibroblast migration. However, in the wound healing experiment, the role of EGF was less significant (see Figure 5 in e, f). These findings indicate that both bFGF and EGF recombinant exosomes promote the proliferation of 293T cells and fibroblasts, and bFGF plays a key role in the migration process.
[0118] 3. Induction of iPSCs by recombinant exosomes
[0119] To further expand the application of recombinant exosomes, this application designed plasmid DNA of Yamanaka factors including Sox2, Oct4, Klf-4, and c-Myc. For 293T cells treated with 1 or 3 micrograms of the Yamanaka factor DNA-exosome complex, no obvious cytotoxicity was observed within 24 hours (see Figure 6 ).
[0120] The expressions of Sox2, Oct4, Klf-4, and c-Myc were examined in 293T cells and 293T cells transfected with Yamanaka factor DNA-exosome complexes. After treatment with Yamanaka factor DNA-exosome complexes, the cells significantly upregulated Klf-4, Sox2, and Oct4 (see Figure 7 b) in Figure 7 . Subsequently, 293T cells were exposed to Yamanaka factor DNA-exosome complexes twice and cultured in dishes, on Geltrex matrix, and in suspension to optimize the experimental conditions for inducing pluripotent stem cells (iPSCs) (see Figure 7 a) in Figure 7 . Western blot results showed that suspension culture significantly increased the expressions of Sox2, Oct4, Klf-4, and c-Myc in 293T cells treated with Yamanaka factor DNA-exosome complexes (see Figure 7 b) in
[0121] . Similar results were also obtained from BJ cells treated with Yamanaka factor DNA-exosome complexes, with the expressions of Klf-4 and Sox2 being upregulated (see Figure 8 b) in
[0122] ). Compared with the flattened control 293T cells, the Yamanaka factor DNA-exosome complex-iPSCs in suspension culture exhibited a spherical morphology similar to that of embryonic stem cells (ESCs) (see
[0121] c) in Figure 8 ). Alkaline phosphatase (AP) is widely used as a biomarker for identifying iPSCs and ESCs.
[0121] AP staining was performed on Yamanaka factor DNA-exosome complex-iPSCs and control 293T cells to further verify the characteristics of iPSCs. 293T cells and induced pluripotent stem cells (iPSCs) were seeded in 6-well plates. Before the experiment, the culture medium was removed and replaced with DMEM / F12 medium. The AP live cell staining reagent was diluted with DMEM / F12 medium and added to the cells. The cells with the added AP reagent were incubated in an incubator at 37 °C for 20 minutes. After removing the reagent, the cells were washed three times with DMEM / F12 medium, 5 minutes each time. Cell images were taken using a fluorescence microscope (Nikon) under the FITC and bright field channels. At least five images were captured under each condition. The Yamanaka factor DNA-exosome complex-iPSCs in suspension culture showed higher AP activity than the untreated cells (see Figure 8 ). The above findings indicate that we can provide a novel, virus-free method for efficiently generating iPSCs.
[0122] After the above steps, the technology of using pDNA or PCR DNA to transfect non-human cells to produce recombinant exosomes has the advantages of good biocompatibility, low immunogenicity, high safety, and large-scale production, providing a new strategy for gene therapy, protein engineering, regenerative medicine, and drug delivery.
[0123] The technical features of the above-described embodiments can be combined arbitrarily. For the sake of brevity of description, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, it should be considered as the scope described in this specification.
[0124] The above-described embodiments only represent several implementation manners of the present application, and their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the patent application. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present application, several modifications and improvements can still be made, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the appended claims.
Claims
1. A method for preparing recombinant exosomes, characterized in that: The steps include: transfecting target cells with exosomes loaded with nucleic acid molecules and culturing them to prepare recombinant exosomes; The nucleic acid molecule includes a promoter sequence, a sequence encoding β-globin, a 5'-UTR, a target gene sequence, a sequence encoding α-globin, a 3'-UTR and a terminator sequence in order from the 5' end to the 3' end.
2. The method for preparing recombinant exosomes according to claim 1, characterized in that: The nucleic acid molecule includes at least one of plasmid DNA, mRNA, siRNA, miRNA and circular RNA.
3. The method for preparing recombinant exosomes according to claim 1, characterized in that: The target gene sequence can encode a target protein, and the target protein is used to promote cell proliferation, differentiation, migration and survival and induce the generation of pluripotent stem cells; Optionally, the target protein includes at least one of epidermal growth factor, basic fibroblast growth factor and Yamanaka factor.
4. The method for preparing recombinant exosomes according to claim 3, characterized in that: The gene encoding the epidermal growth factor includes the EGF gene, the sequence of which is shown in SEQ ID NO: 1; And / or, the gene encoding the basic fibroblast growth factor includes the bFGF gene, the sequence of which is shown in SEQ ID NO: 2; And / or, the gene encoding the Yamanaka factor includes at least one of the Sox2 gene, the Oct4 gene, the Klf-4 gene and the c-Myc gene.
5. The method for preparing recombinant exosomes according to claim 4, characterized in that: The sequence of the Sox2 gene is shown in SEQ ID NO: 3; And / or, the sequence of the Oct4 gene is as shown in SEQ ID NO:4; And / or, the sequence of the Klf-4 gene is shown in SEQ ID NO:5; And / or, the sequence of the c-Myc gene is shown in SEQ ID NO:
6.
6. The method for preparing recombinant exosomes according to any one of claims 1 to 5, characterized in that: The sequence of the nucleic acid molecule is any one of SEQ ID NOs: 7 to 9.
7. The method for preparing recombinant exosomes according to any one of claims 1 to 5, characterized in that: The nucleic acid molecules in the exosomes loaded with nucleic acid molecules are loaded in a manner including microfluidic system, electroporation, ultrasound, liposome fusion or direct incubation.
8. A recombinant exosome, characterized in that: The invention comprises a nucleic acid molecule encapsulated by exosomes, wherein the nucleic acid molecule comprises a promoter sequence, a sequence encoding β-globin, a 5'-UTR, a target gene sequence, a sequence encoding α-globin, a 3'-UTR and a transcription terminator sequence in sequence from the 5' end to the 3' end.
9. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the recombinant exosomes prepared by the recombinant exosome method according to any one of claims 1 to 8 or the recombinant exosomes according to claim 9, and pharmaceutically acceptable auxiliary components.
10. Use of the recombinant exosomes prepared by the method for preparing recombinant exosomes according to any one of claims 1 to 7, the recombinant exosomes according to claim 8, or the pharmaceutical composition according to claim 9 in the preparation of a drug for treating wound repair and healing, tissue repair, wound healing, or preventing scar hyperplasia.
Citation Information
Patent Citations
EGF-Fc fusion protein and High-expression production method of mammal expression system of EGF-Fc fusion protein
CN103343134A
Engineered human endogenous virus-like particles and methods of delivery to cells using same
CN114258398A
Cell-free and vector-free in vitro RNA transcription method and nucleic acid molecule of fibroblast growth factor mRNA
CN114717230A
Improved bFGF coding sequence and application of improved bFGF coding sequence in cell modification
CN118064445A
Treatment of Local Skin Hypotrophy Conditions
US20200369738A1
Cited By
Epidermal growth factor (EGF) and fibroblast growth factor (FGF) overexpressed engineered exosome and preparation method, product and application thereof
CN120966763A
